A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies-Reference-Cited by-同舟云学术

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies

Published:2005-12 Issue:5 Volume:131 Page:609-618
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bouscary Didier,Legros Laurence,Tulliez Micheline,Dubois Stephanie,Mahe Beatrice,Beyne-Rauzy Odile,Quarre Marie C.,Vassilief Dominique,Varet Bruno,Aouba Achille,Gardembas Martine,Giraudier Stephane,Guerci Agnes,Rousselot Philippe,Gaillard Fanny,Moreau Anne,Rousselet Marie C.,Ifrah Norbert,Fenaux Pierre,Dreyfus Francois,

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2005.05817.x/fullpdf

Reference34 articles.

1. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?

2. The evolution of thalidomide and its IMiD derivatives as anticancer agents

3. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes

4. Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes

5. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report;Leukemia Research Reports;2024

2. Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years;Blood Advances;2019-09-19

3. Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant;Critical Reviews in Oncology/Hematology;2019-01

4. Erythropoiesis-Stimulating Agents in Low-Risk MDS;Myelodysplastic Syndromes;2018

5. Myelodysplastic syndromes: pathophysiology, clinical and biological features;Annales de biologie clinique;2015-11